Related Experiment Video
Updated: Aug 6, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Theranostics of prostate cancer: PSMA and new targets
1Institute of Nuclear Medicine, University College London Hospital, London, UK. dimitris.priftakis@nhs.net.
Hellenic Journal of Nuclear Medicine
|July 19, 2026
Abstract:
The aim of this presentation is to transfer the experience of the Institute of Nuclear Medicine at University College London Hospital with prostate cancer theranostics as a leading clinical and academic centre in the UK as well as to open a discussion on the current state and potential future developments in this field.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...